These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Building bridges to the future of medicine: recommendations for boosting development of novel and companion diagnostics. Creeden J Pharmacogenomics; 2012 Nov; 13(14):1651-9. PubMed ID: 23148640 [TBL] [Abstract][Full Text] [Related]
5. Company profile: Sequenom, Inc. Cantor CR Pharmacogenomics; 2012 Apr; 13(5):529-31. PubMed ID: 22462745 [TBL] [Abstract][Full Text] [Related]
6. Personalized medicine: a paradigm for a sustainable pharmaceutical industry? Chackalamannil S; Desai MC Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640 [TBL] [Abstract][Full Text] [Related]
7. Molecular pathology as the driving force for personalized oncology. Oktay MH; Hui P Expert Rev Mol Diagn; 2012 Nov; 12(8):811-3. PubMed ID: 23249199 [TBL] [Abstract][Full Text] [Related]
8. [Discussing the usefulness of companion diagnostics - introductory remarks by chairpersons]. Nobori T; Nomura F Rinsho Byori; 2014 Dec; 62(12):1263-4. PubMed ID: 25823244 [TBL] [Abstract][Full Text] [Related]
9. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232 [TBL] [Abstract][Full Text] [Related]
10. The biggest challenges currently facing companion diagnostic advancement. Halim AB Expert Rev Mol Diagn; 2014 Jan; 14(1):27-35. PubMed ID: 24308333 [TBL] [Abstract][Full Text] [Related]
11. Companion diagnostics: the key to personalized medicine. Foreword. Jørgensen JT Expert Rev Mol Diagn; 2015 Feb; 15(2):153-6. PubMed ID: 25597758 [TBL] [Abstract][Full Text] [Related]
12. Personalised medicine in 2012: editorial to the special issue of New Biotechnology on "molecular diagnostics & personalised medicine". Desiere F; Romano Spica V N Biotechnol; 2012 Sep; 29(6):611-2. PubMed ID: 22504736 [TBL] [Abstract][Full Text] [Related]
14. Company profile: PGXIS Ltd. McCarthy A Pharmacogenomics; 2011 Sep; 12(9):1253-6. PubMed ID: 21919604 [TBL] [Abstract][Full Text] [Related]
15. Regulatory considerations for companion diagnostic devices. Lee EY; Shen HC Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456 [TBL] [Abstract][Full Text] [Related]
16. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics. Halim AB Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153 [TBL] [Abstract][Full Text] [Related]
17. Company Profile: AKESOgen, Inc. Bouzyk M; Boisjoli R Pharmacogenomics; 2012 Jul; 13(10):1115-8. PubMed ID: 22909201 [TBL] [Abstract][Full Text] [Related]
18. Diagnostics and personalized medicine: observations from the World Companion Diagnostics Summit. Curran ME; Platero S Pharmacogenomics; 2011 Apr; 12(4):465-70. PubMed ID: 21521019 [TBL] [Abstract][Full Text] [Related]
19. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Baudhuin LM; Donato LJ; Uphoff TS Expert Rev Mol Diagn; 2012 Jan; 12(1):25-37. PubMed ID: 22133117 [TBL] [Abstract][Full Text] [Related]
20. Diagnostics for a personalized medical future: extending our senses to the molecular scale. Miller BL Stud Health Technol Inform; 2009; 149():297-310. PubMed ID: 19745489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]